Skip to main content
. 2017 Dec 23;9(14):11805–11815. doi: 10.18632/oncotarget.23668

Figure 6.

Figure 6

(A–C) Pooled risk ratio of gefitinib, erlotinib, and afatinib indirectly compared for the ocurrence of skin rash.